Does Pozelimab Interact with Intravenous Immunoglobulin Ivig?
Pozelimab and Intravenous Immunoglobulin Ivig have a major drug interaction according to U.S. FDA drug labeling data. Intravenous immunoglobulin may decrease pozelimab concentrations by interfering with FcRn recycling mechanism. Avoid concomitant use; if unavoidable, monitor for worsening clinical signs and symptoms. The mechanism involves interference with endosomal neonatal fc receptor (fcrn) recycling mechanism of monoclonal antibodies. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Pozelimab Class
- Complement Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Pozelimab and Intravenous Immunoglobulin Ivig occurs because interference with endosomal neonatal fc receptor (fcrn) recycling mechanism of monoclonal antibodies. Clinically, this means intravenous immunoglobulin may decrease pozelimab concentrations by interfering with fcrn recycling mechanism. avoid concomitant use; if unavoidable, monitor for worsening clinical signs and symptoms. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Pozelimab and your doctor is considering prescribing Intravenous Immunoglobulin Ivig (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider